Home > Press > Harris & Harris Group Notes Ensemble Therapeutics and Genentech Drug Discovery Collaboration
Abstract:
Harris & Harris Group, Inc. (NASDAQ: TINY) notes that Ensemble Therapeutics Corporation and Genentech, a member of the Roche Group, announced the initiation of a drug discovery collaboration
Harris & Harris Group Notes Ensemble Therapeutics and Genentech Drug Discovery Collaboration
New York, NY | Posted on May 29th, 2012
he collaboration will deploy Ensemble's proprietary drug discovery platform, including its Ensemblin™ collection of over five million macrocycles, to discover novel drug candidates against Genentech's drug targets. Genentech will have the right to develop and commercialize lead molecules arising from the collaboration. Under the terms of the agreement, Ensemble will receive an undisclosed upfront payment and milestone payments upon the successful achievement of certain development milestones. In addition, Ensemble is eligible to receive royalties on future sales of products that arise from the collaboration. Ensemble's press release can be accessed at www.ensemblediscovery.com/news/pdfs/pr05292012.pdf.
Harris & Harris Group is an investor in privately held Ensemble Therapeutics.
####
About Harris & Harris Group, Inc.
Harris & Harris Group is an early-stage, active investor in transformative nanotechnology companies. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.ensemblediscovery.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
For more information, please click here
Copyright © Harris & Harris Group, Inc.
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013
CRIXlabs Joins the ROCK Health Incubator: ROCK Health is the world’s leading healthcare incubator looking to make meaningful change through scalable, innovative technology. June 5th, 2013
Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home: Glowing Plant seeks funds via crowdfunding and raises almost $400,000 May 31st, 2013
Nanomedicine
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Patents/IP/Tech Transfer/Licensing
Nanoparticle Opens the Door to Clean-Energy Alternatives June 14th, 2013
DRYWIRED™ Receives MILITARY-STANDARD Certifications from QUANTA LABORATORIES for Its Latest Protective Nano-Coating Technology June 5th, 2013
Apple patents point to slimmer battery tech June 1st, 2013
Patent for Coaxial Nanofibre Production: Scientists from Contipro have patented new jet for effective coaxial nanofibers production May 31st, 2013